


AMENDMENTS

In the Claims



Please amend claims 26 and 33, as follows:

26. (Thrice Amended) The polypeptide of claim 20, wherein the polypeptide contains a sequence of at least 2 contiguous amino acids which are identical in forward or reverse orientation to 2 contiguous amino acids of a sequence in human mucin from human milk fat globule (HMFG), wherein said HMFG sequence is contained in SEQ ID NO:33.

33. (Twice Amended) The fusion polypeptide of claim 27, comprising the light chain variable region and the heavy chain variable region of antibody 11D10, wherein the light chain variable region and the heavy chain variable region are contained in SEQ ID NO:2 and SEQ ID NO:4, respectively.

Please add new claims 74-97, as follows:

74. (New) A composition comprising the purified antibody of claim 4 and a pharmaceutically acceptable excipient.

75. (New) A composition according to claim 74, wherein the composition is immunogenic.

76. (New) A composition according to claim 75, further comprising an adjuvant.

77. (New) A polypeptide according to claim 20, wherein the polypeptide comprises three CDRs from the light chain variable region of antibody 11D10 and three CDRs from the heavy chain variable region of antibody 11D10, and wherein the amino acid sequences of the light chain and heavy chain variable regions are contained in SEQ ID NO:2 and SEQ ID NO:4, respectively.

*CB
cont*

78. (New) A fusion polypeptide according to claim 31, wherein the amino acid sequences of the light chain variable region and the heavy chain variable region are contained in SEQ ID NO:2 and SEQ ID NO:4, respectively.

bx 117

79. (New) A fusion polypeptide according to claim 32, wherein the linker polypeptide comprises the amino acid sequence (GGGGS)₃.

80. (New) A humanized antibody according to claim 35, wherein the light chain variable region and the heavy chain variable region are contained in SEQ ID NO:2 and SEQ ID NO:4, respectively.

81. (New) A composition comprising the humanized antibody of claim 35 and a pharmaceutically acceptable excipient.

82. (New) A composition according to claim 81, wherein the composition is immunogenic.

83. (New) A composition according to claim 82 further comprising an adjuvant.

84. (New) A humanized antibody comprising three CDRs from the light chain variable region of 11D10, three CDRs from the heavy chain variable region of 11D10, and framework regions that are human sequences, wherein the humanized antibody is able to stimulate a specific immune response against human milk fat globule (HMFG), wherein the light chain variable region amino acid sequence is contained in an antibody produced by a hybridoma cell line designated ATCC No. HB 12020 or progeny thereof, wherein the heavy chain variable region amino acid sequence is contained in an antibody produced by a hybridoma cell line designated ATCC No. HB 12020 or progeny thereof, and wherein the light chain variable region and the heavy chain variable region are contained in SEQ ID NO:2 and SEQ ID NO:4, respectively.

85. (New) A composition comprising the humanized antibody of claim 84 and a pharmaceutically acceptable excipient.

86. (New) A composition according to claim 85, wherein the composition is immunogenic.

87. (New) A composition according to claim 86, further comprising an adjuvant.

88. (New) An antibody comprising a light chain variable region amino acid sequence contained in SEQ ID NO:2 and a heavy chain variable region amino acid sequence contained in SEQ ID NO:4.

89. (New) A composition comprising the antibody of claim 88 and a pharmaceutically acceptable excipient.

90. (New) A composition according to claim 89, wherein the composition is immunogenic.

91. (New) A composition according to claim 90, further comprising an adjuvant.

92. (New) An antibody comprising three CDRs from the light chain variable region of anti-idiotype antibody 11D10 and three CDRs from the heavy chain variable region of anti-idiotype antibody 11D10, wherein the CDRs from the light chain variable region are contained in SEQ ID NO:2 and the CDRs from the heavy chain variable region are contained in SEQ ID NO:4.

93. (New) A composition comprising the antibody of claim 92 and a pharmaceutically acceptable excipient.

94. (New) A composition according to claim 93, wherein the composition is immunogenic.

95. (New) A composition according to claim 94, further comprising an adjuvant.

96. (New) A composition comprising the polypeptide of claim 77 and a pharmaceutically acceptable excipient.

97. (New) A monoclonal anti-idiotype antibody according to claim 1, comprising the light chain variable region amino acid sequence contained in SEQ ID NO:2 and the heavy chain variable region amino acid sequence contained in SEQ ID NO:4.